STAAR Surgical Announces Strategic Cooperation Agreement With World Eye Hospital Group With 30,000 Refractive Procedures Performed Annually in 21 Clinics, World Eye Hospital Group is the Largest Provider in Southeast Eur

STAAR Surgical Announces Strategic

Cooperation Agreement

With World Eye Hospital Group

With 30,000 Refractive Procedures

Performed Annually in 21 Clinics,

Hospital Group is the Largest Provider in Southeast Europe

MONROVIA, CA, September 7, 2016---STAAR

Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems

for the eye, and World Eye Hospital Group headquartered in Istanbul, Turkey today

announced that they have entered into an agreement to provide STAAR's EVO Visian ICL intraocular lenses as a primary

and premium option for refractive eye treatment.

Eye Hospital Group (D nya G z) is pleased to enter into this Strategic Cooperation Agreement with STAAR Surgical. As

the largest refractive eye surgery provider in Turkey and Southeast Europe, the primary goal of this agreement is to expand and

provide our patients with vision treatment services with the EVO Visian ICL technology to reduce or correct myopia, hyperopia,

and astigmatism with an outstanding vision care treatment. We

have made the decision to offer the EVO lenses to all of our mid-to-high myopic patients as a premium procedure. We look forward

to the co-marketing, branding, clinical validation, surgeon education and patient education plans we have agreed to implement with

STAAR which will support our objective of a substantial increase in EVO refractive procedures," said Mr. Adem Esg n,

Vice Chairman of The Board of World Eye Hospital Group.

"World Eye Hospital Group's

Head of Refractive Surgery, Dr. Efekan o kunseven, is a renowned EVO ICL surgeon and will become the lead trainer

for Southeastern Europe as part of the overall agreement. EVO ICL clinical user's meetings and regional research studies

will enhance the development of clinical validation and new product opportunities for STAAR and World Eye Hospital Group in refractive

surgery. Practice and business development support will be foundational in this partnership" said Caren Mason, President

About STAAR Surgical

STAAR, which has been dedicated solely

to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye with companion

delivery systems. These lenses are intended to provide visual freedom for patients lessening or eliminating the reliance on glasses

or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's

lens used in refractive surgery is called an Implantable Collamer Lens or "ICL". More than 600,000 Visian ICLs

have been implanted to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 employees and markets

lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and

Monrovia, CA. For more information, please visit the Company's website at www.staar.com.

All statements in this press release that are not statements

of historical fact are forward-looking statements, including statements about any of the following: statements regarding products

or potential future sales in Turkey or Southeast Europe, including but not limited to current or future sales to World Eye Hospital

Group, and any statements of assumptions related to or underlying any of the foregoing. Important factors that could cause actual

results to differ materially from those indicated by such forward-looking statements are set forth in the Company's Annual

Report on Form 10-K for the year ended January 1, 2016, under the caption "Risk Factors", which is on file with the

Securities and Exchange Commission and available in the "Investor Information" section of the company's website

under the heading "SEC Filings."

These statements are based on expectations and assumptions as

of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ

materially from those described in the forward-looking statements.